BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's lead program, BGE-102, is an orally available, brain-penetrant small-molecule NLRP3 inhibitor currently in Phase 1 trials for cardiometabolic disease and ophthalmology, specifically targeting atherosclerotic cardiovascular disease and diabetic macular edema. BioAge Labs is also developing novel apelin receptor APJ agonists for obesity, with plans to file Investigational New Drug applications by the end of 2026. The company utilizes a proprietary human-first discovery platform that analyzes longitudinal multi-omics data from human aging cohorts to identify molecular drivers of disease. BioAge Labs maintains ongoing collaborations with Eli Lilly and Company for target discovery and molecule advancement, as well as a target discovery collaboration with Novartis Pharma AG. In June 2025, the company announced an option agreement with JiKang Therapeutics for a novel APJ agonist antibody. The company focuses on chronic cardiometabolic conditions, leveraging insights into aging trajectories to develop treatments for obesity, cardiovascular risk, and retinal diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage bioagelabs.com
Sector Healthcare IR page ir.bioagelabs.com
Tags
biopharmaceuticals, nlrp3 inhibitors, cardiometabolic disease, obesity, ophthalmology, diabetic macular edema, apj agonists, aging biology, small molecules, clinical-stage, BGE-102, QUELL CV, QUELL DME, JiKang Therapeutics, Eli Lilly and Company, Novartis Pharma AG
Press page —

Metrics

Valuation  
Market cap $ 325.793M
Market cap (USD) $ 325.793M
P/E -2.78
PEG —
P/BV 0.94
P/S 37.89
P/OCF -3.18
P/FCF -3.16
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.1%
ROI -29.3%
ROIC -25.3%
Profit margin -896.1%
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -57.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 8.995M — 0 0
Net profit -80.605M -71.109M -63.854M -39.722M
Free cash flow -82.346M -51.888M -37.528M -36.284M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 13.23 5.79 — —
Price performance 12m 1.28 — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 0.00 769,000
Borrowings, current (USD) 6M 6M 2.65M
Borrowings, non-current (USD) 8.2M 2.5M 0.00
Lease liabilities (USD) 194,000 202,000 2.91M
Cash and deposits (USD) 21.6M 354M 189M
Right-of-use assets (USD) 195,000 200,000 2.79M
Net debt (borrowings + leases - cash) (USD) -7.25M -346M -183M
Cash flow detail
Operating cash flow (USD) -37.4M -51.5M -81.6M
Purchases of property, plant and equipment (USD) -166,000 -366,000 -719,000
Change in receivables (cash effect) (USD) — 0.00 -769,000
Change in payables (cash effect) (USD) -393,000 6,000 788,000
Interest paid (cash effect) (USD) -1.16M -1.42M -611,000
Income taxes paid (cash effect) (USD) — 0.00 0.00
Share-based compensation (USD) 3.02M 6.98M 11.7M
Operating cash flow before change in receivables (USD) — -51.5M -80.9M
Free cash flow (OCF - PPE - intangibles) (USD) -37.5M -51.9M -82.3M
Income detail
Research and development expense (USD) 33.9M 59M 74M
Total comprehensive income (USD) -63.9M -71M -80.6M
Comprehensive income to owners (USD) -63.9M -71M -80.6M
Reported Mar 20, 2025 Mar 24, 2026 Mar 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027

QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026

APJ agonist program, an exercise-mimetic approach to obesity, on track for IND submission by year-end 2026

EMERYVILLE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its third quarter 2026 financial results.

“NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6, are already approved for multiple indications, but a once-daily pill that works earlier in the process—and also lowers IL-18 and reduces harmful inflammatory cell death—could help many more people.

BioAge Labs, Inc. — Other Events Bull 3 Bear 0 Clinical/regulatory

BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“DME”), and provided updates on the QUELL-DME Phase 2 trial design.

QUELL-DME Trial Design

•Randomized, controlled, three-arm, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy over 12 weeks of once-daily dosing, with a four-week follow-up.

•The participants are randomized 1:1:1 among the trial’s three arms, which include (i) intravitreal anti-VEGF and oral placebo, (ii) intravitreal anti-VEGF and BGE-102 at 90 mg, dosed daily, and (iii) sham (simulated) intravitreal injection and BGE-102 at 90 mg, dosed daily.

•Primary endpoint is change in best-corrected visual acuity at week 12; exploratory endpoints include measures of retinal parameters and intraocular and plasma biomarkers.

•Topline results expected in the second half of 2027; the results are expected to inform the development strategy in other NLRP3-driven retinal diseases, including geographic atrophy.

September 25, 2026

PDF Version

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings.

• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on Wednesday, September 30 at 1 PM EDT. BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the presentations will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular proof-of-concept data from QUELL-CV are anticipated in the second half of 2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated in the second half of 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAgeʼs additional preclinical programs, which leverage insights from the Companyʼs proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Prompts

BioAge Labs, Inc. (ticker BIOA), listed in United States.

ETFs Holding BioAge Labs, Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.20% 2,187 $ 19.77K Jul 31, 2026
FESM 0.07% 171,445 $ 4.202M Jun 30, 2026
VFMO 0.06% 126,240 $ 1.199M Aug 31, 2026
AVSC 0.01% 59,774 $ 312.02K Nov 16, 2026
DFAS 0.00% 226,545 $ 1.28M Nov 12, 2026
MSSM 0.00% 1,316 $ 12.502K Aug 31, 2026
DFAC 0.00% 63,065 $ 356.317K Nov 12, 2026
DCOR 0.00% 23,733 $ 134.091K Nov 12, 2026
AVUS 0.00% 1,959 $ 10.226K Nov 16, 2026